PEGS Boston 2021 Recap Series
Recap Series Wrap Up – PEGS Boston 2021
We very much enjoyed attending, presenting and networking at PEGS Boston virtual conference and we look forward to an in-person event next year. We tried to make it to as many talks as we could, and were impressed by the achievements and advancements presented. In case you missed it, we posted our notes about a few of our favorite talks in the days following the conference. Here are the highlights. Click through to find our notes, links to the original talks, and notes about how our technology complements the approach.
As one of the keynote speakers at this year’s PEGS, Dr. Baker shared his team’s recent work on the de novo protein design against COVID-19 regarding the antivirals, diagnostic, and vaccines aspects. Notably, Baker with his collaborators have designed a series of mini proteins that can block viral infection by targeting the SARS-CoV-2 receptor binding domain. Read more…
In this talk, Dr. Tovey introduced the iLite® platform developed by Svar Life Science as a cell-based solution to measure neutralizing antibodies in response to adeno-associated virus (AAV) vectors in gene therapy. Current AAV gene therapy faces a number of analytical challenges such as assessing product potency and testing AAV-related immunogenicity. With iLite® technology, Dr. Tovey’s company, Svar Life Science, aims to address these challenges. Dr. Tovey walked us through the molecular construction of the dual-cell system consisting of packaging and responsive cell lines. Read more…
Structure Knowledge is Vital for Design and Development of Better Therapeutics
Dr. Ab’s presentation was a clear and concise presentation on how to fine tune antibody-drug conjugates (ADCs) to develop more potent and precise treatments against cancers. With a focus on developing better treatments, Dr. Ab’s team at ImmunoGen Inc., chose to focus on folate receptor alpha (FRα) due to its high expression in cancers like ovarian cancer, which is linked to a high mortality rate. Read more…
Anthony discussed our antibody protein sequencing technology and their applications such as advancing antibody therapeutic discovery and development, decoding the immune response in vaccinology studies, and monitoring relapse in patients suffering from cancers like multiple myeloma (MM). In his presentation, Anthony hinted at some exciting data stemming from our REpAb® platform, relying only on proteomics and machine learning. Watch the presentation …
Aids and Cancer Antibody Engineering, Support from REmAb® Sequencing
Dr. Nabel’s talk focused on ModeX Therapeutics’ potent trispecific antibodies. These antibodies are on the rise in the therapeutic world and will continue being used as they can target more than one epitope. Monoclonal-based therapy of viruses such as HIV typically results in escape mutants, and thus poor treatment outcomes. Unlike monoclonals, trispecifics drastically decrease the possibility of escape mutants arising. Furthermore, they could be delivered to patients in a simpler fashion in contrast to monoclonal cocktails. Read more…
See you next year!
We’ve already confirmed our attendance at next year’s event. See you in Boston in May 2022.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 9000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics